Small Cell Lung Cancer Flashcards
1
Q
Describe the patient population, study arms, primary endpoints and results of the ADRIATIC trial
A
ADRIATC
Consolidation immunotherapy in limited stage small cell lung cancer patients who have completed definitive chemotherapy and radiation
1:1:1 randomized to either durvalumab or durvalumab + tremelimumab or placebo for up to 24 months
primary endpoint: progression free survival and overall surival
Durvalumab versus Placebo; median OS 55.9 months versus 33.4 months. PFS; 16.6 months versus 9.2 months
Cheng Y, NEJM 2024
https://www.nejm.org/doi/full/10.1056/NEJMoa2404873#summary-abstract